Evidence map›Paper›PMID 34179028›Full record

ArticleFrontiers in medicine2021

Subacute Cutaneous Lupus Erythematosus-Like Eruption Induced by EGFR -Tyrosine Kinase Inhibitor in

Alessandra Ferro, Angela Filoni, Alberto Pavan, Giulia Pasello, Valentina Guarneri, PierFranco Conte, Mauro Alaibac, Laura Bonanno

Open access · goldAbstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Alessandra FerroDepartment of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Padova, Italy.
Angela FiloniMelanoma and Sarcoma Surgical Oncology Unit - Veneto Institute of Oncology, IOV-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padua, Italy.
Alberto PavanMedical Oncology 2, Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padova, Italy.
Giulia PaselloMedical Oncology 2, Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padova, Italy.
Valentina GuarneriDepartment of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Padova, Italy.
PierFranco ConteDepartment of Surgery, Oncology and Gastroenterology, Università degli Studi di Padova, Padova, Italy.
Mauro AlaibacUnit of Dermatology, University of Padua, Padua, Italy.
Laura BonannoMedical Oncology 2, Istituto Oncologico Veneto Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Padova, Italy.
University of Padua · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Oncologico Veneto · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

EGFR tyrosine kinase inhibitors (TKIs) are the front-line treatment in

Indexed as

cutaneous drug reactionsimmune- related adverse eventsimmunotherapyosimertinibtargeted therapy

Identifiers

PMID34179028
PMCPMC8220808
OpenAlexW3171563726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.